NeuroPace Q4 Loss Narrows to $0.08, Revenues Jump 23.8% to $26.6M
NeuroPace posted an adjusted Q4 loss of $0.08 per share, beating the consensus estimate by $0.06 and narrowing from a $0.18 loss a year earlier. Revenue rose 23.8% to $26.59 million, 2.5% above estimates, though shares are down 8.4% year-to-date versus a 0.5% S&P 500 gain.
1. Q4 2025 Results
NeuroPace reported an adjusted EPS loss of $0.08 in Q4 2025, beating the consensus estimate by $0.06 and improving from a $0.18 loss a year earlier. Revenue rose 23.8% year-over-year to $26.59 million, topping estimates by 2.5%.
2. Consistent Estimate Beats
The company has exceeded consensus EPS estimates in three of the last four quarters and has topped revenue expectations in each of the past four periods, reflecting a trend of operational improvements and tighter cost management.
3. Share Performance and Outlook Impact
NeuroPace shares have declined 8.4% year-to-date compared with a 0.5% gain for the S&P 500, influenced by unfavorable earnings estimate revisions that have led to a sell rating and could pressure near-term stock performance.
4. 2026 Consensus Guidance
Current consensus forecasts call for a loss of $0.23 per share on $21.7 million in revenue for the upcoming quarter and a $0.71 loss on $98.65 million in revenue for the full 2026 fiscal year, setting the stage for the next earnings cycle.